Malin (DUB:MLC) Institutional Ownership : 0.01% (As of Apr. 15, 2025)

View and export this data going back to 2014. Start your Free Trial

What is Malin Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Malin's institutional ownership is 0.01%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Malin's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Malin's Float Percentage Of Total Shares Outstanding is 0.00%.

Malin Institutional Ownership Historical Data

The historical data trend for Malin's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Malin Institutional Ownership Chart

Malin Historical Data

The historical data trend for Malin can be seen below:

	2021-03-31	2021-04-30	2021-05-31	2021-06-30	2021-07-31	2021-08-31	2021-09-30	2021-10-31	2021-12-31	2023-03-31
Institutional Ownership	0.25	0.25	0.04	0.01	0.01	0.01	0.20	0.69	0.68	0.01

Malin Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Malin Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Malin Corporation PLC (DUB:MLC) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

N/A

Address

50 Richmond Street South, The Lennox Building, Dublin, IRL, D02 FK02

Website

http://www.malinplc.com

Malin Corporation PLC is a life sciences company. Its investee companies are in science and discovery, clinical and commercial sectors. The company's approach is to create shareholder value through the selective long-term application of capital and operational expertise to private, pre-trade sale operating businesses in the life sciences industry. The company derives all of its revenue from its subsidiary. The company focuses on oncology, immunology, and genetic diseases where it believes that life science and healthcare technologies will deliver transformative treatments for patients.

Malin Headlines

No Headlines